Strategic Plan
FY2018–FY2022
GHIT utilizes Japanese science and pharmaceutical capabilities to accelerate product development (i.e., drugs, vaccines, and diagnostics) for HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases
R&D: Investments in Product Development
Partnership for Delivery
- Strengthen capacity to appraise access and delivery strategies for late-stage candidates
- 10 access and delivery strategies for late-stage investments reviewed by PLSC, and reported to the Board of Directors
- Leverage UNDP and other global network partners for product delivery preparedness
- Six access and delivery strategies shared and discussed with UNDP and other global partners
- Six meetings convened between development partners and relevant global partners for each of the access and delivery strategies aforementioned with the goal of in-country access and delivery support
- Present GHIT's access and delivery strategies at more than 20 conferences or events
Excellence through Good Governance
- Ensure and further enhance corporate governance and institutional development
- Two successful audits by the Cabinet Office of Japan (conducted every three years)
- Five successful financial audits by an external and independent auditor
- Five successful internal audits by the GHIT management team (results reported to Chief Executive Officer & Board of Directors)
- Biennial review and sign-off by Board of Directors of updated GHIT policies including Governance Manual
Financial Strategies
- Maximize efficiencies in fund management and co-funding strategies
- Maintain overhead cost (at or below 5%)
Maintain uniquely low overhead cost in order to maximize investments in R&D - Increase leveraging factor (to 2.0)
Leveraging factor = ( GHIT’s investment + co-investment by other organizations) / (GHIT’s investment) = 1.5 as of December, 2017
- Develop and execute a replenishment plan for GHIT 3.0
- Successfully replenish GHIT 3.0 (FY2023 - FY2027)
Ensure sustainable operations of GHIT and continued acceleration of product development
Disclaimer: This document contains forward-looking statements and actual results may be materially different from those expected in the forward-looking statements due to a number of risks and uncertainties, including, but not limited to, whether we can sustain funding, achieve successful progression of products through the R&D process, and receive regulatory approvals.
